To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

NCT07406438 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

48

Enrollment

NETWORK

Sponsor class

Conditions

Neovascular Age-Related Macular Degeneration (nAMD)

Interventions

DRUG: GB10

Sponsor

Shenzhen Kexing Pharmaceutical Co., Ltd.